Cancer Immunotherapy Market was valued at USD 123.45 billion in 2022 and is estimated to reach approximately USD 236.13 billion by 2031, at a CAGR of 9.76% from 2023 to 2031.
Cancer Immunotherapy Market 2024" report, published by Econ Market Research, delivers an in-depth analysis of factors influencing the market environment, competitive dynamics, and growth forecasts using both historical and current data. It explores technological advancements, emerging innovations, and projects the compound annual growth rate (CAGR). The report draws on reliable sources, including company websites, annual reports, journals, and other credible publications, all meticulously verified by market experts. This comprehensive market research is crucial for businesses and organizations, aiding in informed decision-making, addressing complex business challenges, and mitigating the risk of failure.
To learn more about this report, request a sample copy @ https://www.econmarketresearch.com/request-sample/EMR00370
Cancer immunotherapy is a cancer treatment, which improves the immune system's ability to fight cancer. This therapy is desirable than the old technique due to it provides long-term cancer protection, has less side effects, and treats a broader range of cancer. Cancer immunotherapy is used in several types of cancers includes melanoma, prostate cancer, breast cancer, colorectal cancer, lung cancer, head & neck cancer, and more. Immunotherapy works by leading the immune system to cancer-specific targets, activating the immune system to mobilize the target, and activating a response capable of destroying cancer cells.
Competition Analysis
Key competitors or manufacturers featured in the study include:
Pfizer Inc.; AstraZeneca; Merck & Co. Inc; F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; Novartis AG; Lilly; Johnson & Johnson Services, Inc; Immunocore, Ltd., and others.
Report Breakdown
This report studies the global Cancer Immunotherapy market, providing detailed insights and forecasts based on:
- Geography: North America, South America, Europe, Asia-Pacific, Middle East, and Africa
- By Technology Type (Monoclonal Antibodies, Cytokines & Immunomodulators, Others),
- By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Others),
- By End User (Hospitals, Cancer Research Centers, Clinics),
Chapters Include:
· Introduction to Cancer Immunotherapy
· Cancer Immunotherapy Market Size and Share by Type (2020)
· Cancer Immunotherapy Market by Application/End Users
· Cancer Immunotherapy Sales and Market Share by Applications (2013-2023)
· Cancer Immunotherapy Sales and Growth Rate (2014-2024)
· Cancer Immunotherapy Competition by Players/Suppliers, Region, Type, and Application
· Cancer Immunotherapy Volume, Value, and Sales Price by Region
· Cancer Immunotherapy Players/Suppliers Profiles and Sales Data
· Company Basic Information, Manufacturing Base, and Competitors List
· Market Sales, Revenue, Price, and Gross Margin by Product Type
· Cancer Immunotherapy Manufacturing Cost Analysis
· Cancer Immunotherapy Key Raw Materials Analysis
· Cancer Immunotherapy Supply Chain, Sourcing Strategy, and Downstream Buyers
· Market Forecast (2024-2032)
Cancer Immunotherapy Market Recent Developments
· In October 2023, Merck's anti-PD-1 therapy KEYTRUDA was approved for the treatment of patients with respectable non-small cell lung cancer (NSCLC) as neoadjuvant treatment and adjuvant treatment following surgery.
· In October 2023, Pfizer has gained approval from the U.S. Food and Drug Administration (FDA) for the use of MEKTOVI (binimetinib) in combination with BRAFTOVI (encorafenib) to treat metastatic non-small cell lung cancer (NSCLC) in adults who possess a BRAF V600E mutation. Detection of this mutation is confirmed through an FDA-approved test.
· In December 2023, the xU.S. FDA approved the FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer by Takeda
Key Questions Answered in This Report:
- What will the market size and growth rate be in 2032?
- What are the key market trends?
- What is driving the Cancer Immunotherapy market?
- What are the challenges to market growth?
- Who are the key vendors in the market?
- What are the outcomes of the five forces analysis of the Cancer Immunotherapy market?
- What are the market opportunities and threats faced by vendors? Get detailed insights into factors influencing market shares across the Americas, APAC, and EMEA.
About Econ Market Research:
Econ Market Research is a leading provider of comprehensive market intelligence, offering expert analysis and insights across a diverse range of industries. With a team of seasoned analysts and industry experts, we deliver high-quality market research reports, customized research solutions, and consulting services tailored to our clients' specific needs. Our commitment to quality, accuracy, and client satisfaction sets us apart, making us a trusted partner for businesses seeking actionable intelligence to navigate the complexities of today's global markets.
Contact Us:
For inquiries, partnerships, or to learn more about our services, please contact us at Sales@econmarketresearch.com .
Phone: (+1) 812-506-4440
Mobile: +91-7875074426
Comments
0 comment